www.cardiometabolichealth.org



### Foundations of Cardiometabolic Health Certification Course

Certified Cardiometabolic Health Professional (CCHP)

(ag


# Connected Insulin Pens in 2023 and Beyond

Viral N Shah, MD Barbara Davis Center for Diabetes University of Colorado

### **Disclosure Statement**

- <u>Advisory Boards</u>: Sanofi, Medscape, LifeScan, DKSH Singapore, and NovoNordisk
- <u>Co-Director, Diabetes Dialog</u>: 3-days educational program for Endocrine Fellows sponsored by many industries
- <u>Speaking</u>: Dexcom, Insulet, Tandem Diabetes Care and Embecta
- <u>Research Grants</u>: Eli-Lilly, NovoNordisk, Insulet, Tandem Diabetes Care, Dexcom, Alexion, NIH and JDRF

### **Evolution of Insulin Delivery Systems**




# Case

- 74-year-old female with 28 years of type 1 diabetes
- MDI with insulin glargine U100 and Insulin Lispro
- A1c of 7.6%
- Mild NPDR
- Other medical conditions: hypothyroidism, hypertension, dyslipidemia, and BL hip arthritis
- Retired and enjoys traveling
- Didn't like pump in the past


- Difficulty remembering
- Injection site reactions
- Fear of hypoglycemia
- Interference with daily life
- Cultural

- Lack of familiarity with devices
- Bias
- Therapeutic/Clinical inertia




- Complex health care system
- Time consuming
- Cost


### **Missed Insulin Doses**



- 10-59% of individuals with T1D reported missing at least 1 bolus dose per week
- 10-30% of individuals with T1D reported missing at least 1 basal dose per month
- 1-30% of individuals with T2D reported missing at least 1 basal insulin dose per month



Unpublished data




~ 2 bolus doses per week would lead to increase in A1c by 0.3-0.4%


~30% of missed insulin doses would lead to increase in A1c by 1.8%.

### **Insulin dosing information: A missing link**


A1c of 7.6%








# **Connected Insulin Pen Concept**




# **Currently Available Connected Pens in the US**


# InPen



- ✓ Reusable pen injector for by people with diabetes under the supervision of an adult caregiver, or by a patient age 7 and older for the self-injection
- ✓ Insulin lispro U-100, insulin aspart U-100, and fast-acting insulin aspart U-100 3.0 mL cartridges
- Insulin dose calculation based on carb ratio, correction factor, and active insulin time
- $\checkmark$  Can be used for fixed doses
- ✓ Insulin dose tracking, reminders
- ✓ Used with Dexcom G6 and Medtronic Guardian 3 CGM
- ✓ Downloadable reports that can be shared
- ✓ Once a year replacement

#### **Interpretation of InPen Data**





### **Bigfoot Unity**




- Approved for age 12 and above
- Smart Pen cap
- Basal (black cap) and bolus (white cap)
- Bolus pen cap can be used with Freestyle Libre 2 CGM (pen can scan the sensor)
- Clinic based prescription model
- No half units
- Compatible with almost all insulin pens
- Rechargeable

### **Bigfoot Clinic Hub**



### **Lilly Tempo**








- Indicated for age 18 and above
- Reusable smartpen cap
- Works with Lilly U100 insulins (glargine, lispro, fast-acting lispro-aabc)
- Connects to its app with Bluetooth
- Integration with BGMs and CGM (Dexcom)
- Battery up to 8 months
- Battery life indicator (green-okay, Amberlow battery)
- No half units or dosing recommendations

#### **Tempo Insight**

					Sun Jung 🗸		
8	Patient List 🏳 Pending Registration	n 💿 Help Center					
C	verview Logbook Medications	Health Info					
	Patient Profile Kevin Johnson  Constraints DOB: Feb 19, 1963 Gender: Male Gender: Male East Login: Feb 18, 2022 Email: kjohnson@example.com Last SMART Visit Report sent: Mobile: 342-555-5467 Last BG entry: Feb 18, 2022		2022 Report sent: Feb 17, 2022	Diabetes Type: Type Registered Date: No Product ID: W00000 Treatment Plan: Basa	v 13, 2021		
	Glucose Summary ( Dec 21, 2021 - Feb	18, 2022 )			Last 30 Days: Insulin Summary		
	Dec 21, 2021 - Jan 19, 2022 Avg Glucose (mg/dL): <b>301</b> The American Diabetes Association recomme range <4%. For older or higher risk individuals <1%. Source: Battelino T, et al., 2019 doi:10.23	34% Very High 0-350 mg/dL) 22% High 1081-250 mg/dL) 43% In Target (70-180 mg/dL) 2% Low (54-69 mg/dL) 0% Venjcow (54-69			Average Insulin Units / Day Breakfast (S units / 16 doess taken) Chuch (12 units / 28 doess taken) Chuch (12 units / 29 doess taken) Chuch (12 units / 29 doess taken) Chuch (13 units / 17 doess taken) Chuch (13 units / 17 doess taken) Saasidigs - 28 9 unitslidigs Other boluses/diay - 31 unitslidigs		
	Content © 2022 Welldoc, Inc. ©	2022, Eli Lilly and Company. Al	FAQ   Conta	FAQ   Contact Us   Terms of Use   Privacy Policy   Third-Party Notices			



# **Connected Pen caps**



"Advantages and Disadvantages of Connected Insulin Pens in Diabetes Management" Kathryn Lingen<sup>1</sup>, Talia Pikounis<sup>2</sup>, Natalie Bellini<sup>3</sup>, and Diana Isaacs<sup>4</sup>

Close Concerns, <u>katie.lingen@closeconcerns.com</u>
 Close Concerns, <u>talia.pikounis@closeconcerns.com</u>
 University Hospitals, <u>natalie.bellini@uhhospitals.org</u>
 Cleveland Clinic, <u>ISAACSD@ccf.org</u>
 Corresponding author: Diana Isaacs (ISAACSD@ccf.org )
 10685 Carnegie Ave. X20 Cleveland, OH 44106
 Short Title: Connected Insulin Pen Review
 Four keywords describing manuscript: connected insulin pens, pen caps
 Word Count (excluding references and figure legends): 4,446

# **Evidence on connected pens**

Study, year	Device	Sample Size	Type 1 or type 2 diabetes	Type of Trial	Primary Outcome	Secondary Outcome
Adolfsson (2020) <sup>26</sup>	NovoPen 6	94	T1D	Prospective, proof-of concept study	Time in Range (P < 0.001)	Missed bolus doses (P = 0.1352), Time Above Range $(P = 0.003)$ , Time Below Range $(P = 0.005)$
Gomez- Peralta (2020) <sup>30</sup>	Insulclock	16	T1D	Randomized pilot study	Time in Range (P = 0.038)	Missed bolus doses, Time Above Range (P = 0.0026), Time Below Range
Jendle (2021) <sup>19</sup>	NovoPen 6	94	T1D	Prospective, proof-of concept study (continuation of Adolfsson et al. 2020)	Cost effectiveness, Time in Range	Mortality, Quality of Life, Time Above Range, Time Below Range

Vigersky	InPen	529	T1D or	Observational	Time in	Time Above
	IIIPell	529	1			
(2021)28			T1D	study	Range (P <	Range, Time
					0.05)	Below
						Range, Total
						insulin doses
						(all P<0.05)
Ekberg	NovoPen	32	T1D	Prospective,	Missed bolus	Time in
(2022)27	6			proof-of-	doses (P <	Range
				concept study	0.001)	(p=0.005),
					-	Time Above
						Range
						(p=0.002),
						Time Below
						Range (ns)
Galindo	Insulclock	80	T2D	Randomized,	Missed bolus	A1c
(2023)29				cross over	doses (ns)	(P = 0.006),
(/				pilot		Mean
				phot		glucose
Chien	InPen	1,681	T1D or	Potrornostire	Number of	<u> </u>
	InPen	1,081	T2D	Retrospective, real-world		Cost savings
(2023)20			120		severe	
				analysis	hypoglycemia	
					episodes	
					(P = 0.008)	
Baliga	Bigfoot	58	T1D or	Retrospective,	Alc (P <	Time in
(2023) 31	Unity		T2D	real-world	0.001)	Range (P <
				analysis		0.05), Time
						Above
						Range (P <
						0.05), Time
						Below
						Range,
						Average
						glucose (P <

# **My Opinion**

- Connected pens are very helpful to view insulin dosing and allows clinicians to optimize diabetes care
- Helpful to patients in remembering and calculating insulin dose. Also, it may help to avoid insulin stacking.
- Connected pen without CGM may have limited utility
- Connected insulin pens would be beneficial in selective patients
  - Those who are missing insulin often
  - Higher A1c
  - Problematic hypoglycemia and insulin stacking issues